AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca has completed a clinical study titled ‘A Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389 (CAMPOLINA).’ The study aimed to assess the safety and tolerability of AZD2389 in individuals with varying degrees of hepatic impairment compared to those with normal liver function. This research is significant as it helps determine the drug’s suitability for patients with liver conditions.
The intervention under investigation is AZD2389, a drug administered as a single oral dose. It is designed to evaluate its pharmacokinetics and safety profile in participants with different levels of liver function.
The study followed a non-randomized, open-label, parallel group design. Participants were divided into cohorts based on their liver function, ranging from normal to severe hepatic impairment. The primary purpose was to gather safety and tolerability data without any masking involved.
The study began on February 3, 2025, with its primary completion and last update recorded on September 23, 2025. These dates are crucial as they mark the progression and conclusion of the study, providing a timeline for data collection and analysis.
The completion of this study could influence AstraZeneca’s stock performance positively, as successful results may enhance investor confidence in the company’s pipeline. It also positions AstraZeneca competitively in the pharmaceutical industry, particularly in the development of treatments for patients with hepatic conditions.
The study is now completed, with further details available on the ClinicalTrials portal.